_256_384.jpg)
Medical Device | November 25, 2024
Sourav Ganguly launches Beurer India's GL 22 Blood Glucose Monitor
The GL 22 Blood Glucose Monitor combines German precision with advanced technology designed to meet local needs
The GL 22 Blood Glucose Monitor combines German precision with advanced technology designed to meet local needs
This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The paper highlights how conditions common across India—including anemia, inherited hemoglobin disorders, and glucose-6-phosphate dehydrogenase (G6PD) deficiency—can significantly distort HbA1c readings
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic
Subscribe To Our Newsletter & Stay Updated
